Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STI 9167

Drug Profile

STI 9167

Alternative Names: COVISHIELD - Sorrento Therapeutics; COVISHIELD antibody - Sorrento Therapeutics; STI-9167; STI-9199

Latest Information Update: 21 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mount Sinai Health System
  • Developer Sorrento Therapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 13 Feb 2023 Sorrento Therapeutics withdraws a phase II trial for COVID-2019 infections (In adolescents, In adults, In the elderly) prior to enrolment in USA (Intranasal,Liquid) (NCT05372783)
  • 14 Oct 2022 Pharmacodynamics data from a preclinical studies in COVID-2019 infections released by Sorrento Therapeutics
  • 13 May 2022 Sorrento Therapeutics plans a phase II trial for COVID-2019 infections (In adolescents, In adults, In the elderly) (Intranasal,Liquid) in July 2022 (NCT05372783)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top